Your experience on this site will be improved by allowing cookies.
N E W S
New video - Ruxolitinib cream, a first treatment approved in Europe for vitiligo. Intervention recorded in Paris on June 3, 2023, during the Annual Meetings of Vitiligo organized by the French Association of Vitiligo.
2 new studies start in the treatment of vitiligo Study for the treatment of external genitalia. Study for classically resistant areas (wrist, back of hands, elbows and knees). More information in the section “Clinical trials in progress" or "Upcoming trials” or by calling 04 92 03 62 25
Last oportunities to participate to the ERASE vitiligo study patients between 18 to 40 with a vitiligo for last than 6 months. Please contact Mr Houis Adrien ( houis.a@chu-nice.fr )
After the FDA approval, ruxolitinib cream just received the EMA approval for treating vitiligo for patients above 12
Vitiligo is a relatively frequent skin disorder. It affects 0.5 to 2% of the worldwide population. Women and men are equally affected. Vitiligo presents with white patches…
Your contributions to Vitiligo Support are tax deductible. Your generosity allows raising awareness on vitiligo, providing support and education and supporting research.
With the identification of biologic and molecular mechanisms involved in the pathophysiology of vitiligo, new treatments are currently developed. Among them, systemic treatments for patients with widespread and/or very active disease, but also topical approaches for repigmenting patches resistant to current treatments. These new treatments are first proposed in clinical trials. These clinical trials are highly supervised and allow proposing the latest advances in optimum safety conditions. At the time, supporting fundamental and translational researches remains mandatory to better understand the mechanisms involved in the depigmentation of the skin but also to study the pathways that allow melanocytes to recolonize the affected skin for repigmenting the lesional patches.